A new treatment against clostridium difficile;Un nouveau venu dans la lutte contre le clostridium difficile

Actualite Chimique

Volumn , Issue 360-361, 2012, Pages 83-89

  Erb, William ^a   Zhu, Jieping ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b INSTITUTE OF CHEMICAL SCIENCES AND ENGINEERING   (Switzerland)

Author keywords

Antibiotics therapy; CDD; Clostridium difficile; Diarrheas; Fidaxomicin; Infections; Tiacumicin

Indexed keywords

EID: 84863264014     PISSN: 01519093     EISSN: 21052409     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Taube G., Collateral damage: The rise of resistant C. difficile, Science, 2008, 321, p. 360.
2. Waksman S. A., What is an antibiotic or an antibiotic substance?, Mycologia, 1947, 39, p. 565.
3. Walsh C., Where will new antibiotics come from?, Nature Rev. Microbiol., 2003, 1, p. 65.
4. Clatworthy A. E., Pierson E., Hung D. T., Targeting virulence: a new paradigm for antimicrobial therapy, Nature Chem. Biol., 2007, 3, p. 541.
5. Fleming D. M., The state of play in the battle against antimicrobial resistance: a general practitioner perspective, J. Antimicrob. Chemother., 2007, 60, Suppl. 1, p. i49.
6. Coates A., Hu Y., Bax R., Page C., The future challenges facing the development of new antimicrobial drugs, Nature Rev. Drug Discovery, 2002, 1, p. 895.
7. Butler M. S., Buss A. D., Natural products - The future scaffolds for novel antibiotics?, Biochem. Pharmacol., 2006, 71, p. 919;
8. Clardy J., Fischbach M. A., Walsh C. T., New antibiotics from bacterial natural products, Nature Biotech., 2006, 24, p. 1541;
9. Lewis K., Ausubel F. M., Prospects for plant-derived antibacterials, Nature Biotech., 2006, 24, p. 1504;
10. Lomovskaya O., Zgurskaya H. I., Totrov M., Watkins W. J., Waltzing transporters and "the dance macabre" between humans and bacteria, Nature Rev. Drug Discovery, 2007, 6, p. 56;
11. Brown E. D., Wright G. D., New targets and screening approaches in antimicrobial drug discovery, Chem. Rev., 2005, 105, p. 759;
12. Cisar J. S., Tan D. S., Small molecule inhibition of microbial natural productbiosynthesis - An emerging antibiotic strategy, Chem. Soc. Rev., 2008, 37, p. 1320.
13. Pour des revues sur les diarrhées causées par le C. difficile, voir: Poutanen S. M., Simor A. E., Clostridium difficile-associated diarrhea in adults, CMAJ, 2004, 171, p. 51;
14. Mylonakis E., Ryan E. T., Calderwood S. B., Clostridium difficile-associated diarrhea: A review, Arch. Intern. Med., 2001, 161, p. 525.
15. Owens R. C. Jr., Donskey C. J., Gaynes R. P., Loo V. G., Muto C. A., Antimicrobial-associated risk factors for Clostridium difficile infection, Clin. Infect. Dis., 2008, 46, Suppl. 1, p. S19.
16. Lors d'une infection par le C. difficile, deux toxines sont produites. Une certaine « polémique » sur leur toxicité a récemment pris fin avec l'étude menée par Kuehne et Cartman établissant l'importance de considérer les deux toxines dans ce type d'infections. Voir Kuehne S. A., Cartman S. T., Heap J. T., Kelly M. L., Cockayne A., Minton N. P., The role of toxin A and toxin B in Clostridium difficile infection, Nature, 2010, 467, p. 711 et réf. citées.
17. Gerding D. N., Muto C. A., Owens R. C. Jr., Measures to control and prevent Clostridium difficile infection, Clin. Infect. Dis., 2008, 46, Suppl. 1, p. S43.
18. Wenisch C., Parschalk B., Hasenhundl M., Hirschl A. M., Graninger W., Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea, Clin. Infect. Dis., 1996, 22, p. 813.
19. Bartlett J. G., The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection, Clin. Infect. Dis., 2008, 46, p. 1489;
20. Al-Nassir W. N., Sethi A. K., Li Y., Pultz M. J., Riggs M. M., Donskey C. J., Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficileassociated disease, Antimicrob. Agents Chemother., 2008, 52, p. 2403;
21. Barbut F., Richard A., Hamadi K., Chomette V., Burghoffer B., Petit J.-C., Epidemiology of recurrences or reinfections of Clostridium difficileassociated diarrhea, J. Clin. Microbiol., 2000, 38, p. 2386.
22. Gerding D. N., Muto C. A., Owens R. C. Jr., Treatment of Clostridium difficile infection, Clin. Infect. Dis., 2008, 46, Suppl. 1, p. S32.
23. Parenti F., Pagani H., Beretta G., Lipiarmycin, a new antibiotic from actinoplanes I. Description of the producer strain and fermentation studies, J. Antibiot., 1975, 28, p. 247;
24. Coronelli C., White R. J., Lancini G. C., Parenti F., Lipiarmycin, a new antibiotic from actinoplanes II. Isolation, chemical, biological and bichemical characterization, J. Antibiot., 1975, 28, p. 253.
25. Omura S., Imamura N., Oiwa R., Kuga H., Iwata R., Masuma R., Iwai Y., Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. I. Production, isolation, and physicochemical and biological poperties, J. Antibiot., 1986, 39, p. 1407;
26. Takahashi Y., Iwai Y., Omura S., Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. II. Taxonomic study of the producing microorganism, J. Antibiot., 1986, 39, p. 1413.
27. Theriault R. J., Karwowski J. P., Jackson M., Girolami R. L., Sunga G. N., Vojtko C. M., Coen L. J., Tiacumicins, a novel complex of 18-membered macrolide antibiotics I. Taxonomy, fermentation and antibacterial activity, J. Antibiot., 1987, 40, p. 567;
28. Hochlowski J. E., Swanson S. J., Ranfranz L. M., Whittern D. N., Buko A. M., McAlpine J. B., Tiacumicins, a novel complex of 18-membered macrolide antibiotics II. Isolation and structure determination, J. Antibiot., 1987, 40, p. 575.
29. Kurabachew M., Lu S. H., Krastel P., Schmitt E. K., Suresh B. L., Goh A., Knox J. E., Ma N. L., Jiricek J., Beer D., Cynamon M., Petersen F., Dartois V., Keller T., Dick T., Sambandamurthy V. K., Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis, J. Antimicrob. Chemother., 2008, 62, p. 713.
30. 13C nmr spectroscopy and isolation of methyl 2-O-methyl-4-O- homodichloroorsellinate-β-rhamnoside, J. Antibiot., 1983, 36, p. 1312;
31. Arnone A., Nasini G., Cavalleri B., Structure elucidation of the macrocyclic antibiotic lipiarmycin, J. Chem. Soc. Perkin Trans. I, 1987, p. 1353.
32. Shue Y.-K., Hwang C.-K., Chiu Y.-H., Romero A., Babakhani F., Sears P., Okumu F., 18-Membered macrocycles and analogs thereof, Brevet WO 2006085838 A1, 2006, Optimer Pharmaceuticals Inc.
33. Xiao Y., Li S., Niu S., Ma L., Zhang G., Zhang H., Zhang G., Ju J., Zhang C., Characterization of tiacumicin B biosynthetic gene cluster affording diversified tiacumicin analogues and revealing a tailoring dihalogenase, J. Am. Chem. Soc., 2011, 133, p. 1092;
34. Nui S., Hu T., Li S., Xiao Y., Ma L., Zhang G., Zhang H., Yang X., Ju J., Zhang C., Characterization of a sugar-O-methyltransferase TiaS5 affords new tiacumicin analogues with improved antibacterial properties and reveals substrate promiscuity, ChemBioChem, 2011, 12, p. 1740.
35. Villain-Guillot P., Gualtieri M., Bastide L., Leoneti J.-P., In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm, Antimicrob. Agents Chemother., 2007, 51, p. 3117.
36. Shue Y. K., Sears P. S., Shangle S., Walsh R. B., Lee C., Gorbach S. L., Okumu F., Preston R. A., Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses, Antimicrob. Agents Chemother., 2008, 52, p. 1391;
37. Louie T., Miller M., Donskey C., Mullane K., Goldstein E. J. C., Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection, Antimicrob. Agents Chemother., 2009, 53, p. 223.
38. Babakhani F., Gomez A., Robert N., Sears P., Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile, J. Med. Microbiol., 2011, 60, p. 1213.
39. a) Finegold S. M., Molitoris D., Vaisanen M.-L., Song Y., Liu C., Bolanos M., In vitro activities of OPT-80 and comparator drugs against intestinal bacteria, Antimicrob. Agents Chemother., 2004, 48, p. 4898;
40. Tannock G. W., Munro K., Taylor C., Lawley B., Young W., Byrne B., Emery J., Louie T., A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin, Microbiology, 2010, 156, p. 3354.
41. Sergio S., Pirali G., White R., Parenti F., Lipiarmycin, a new antibiotic from actinoplanes III. Mechanism of action, J. Antibiot., 1975, 28, p. 543;
42. Talpaert M., Campagnari F., Clerici L., Lipiarmycin: an antibiotic inhibiting nucleic acid polymerases, Biochem. Biophys. Res. Commun., 1975, 63, p. 328;
43. Sonenshein A. L., Alexander H. B., Initiation of transcription in vitro is inhibited by lipiarmycin, J. Mol. Biol., 1979, 127, p. 55.
44. Villain-Guillot P., Bastide L., Gualtieru M., Leonetti J.-P., Progress in targeting bacterial transcription, Drug Discov. Today, 2007, 12, p. 200.
45. e ed.), 2005, p. 1221.
46. Figure 8 reprinted from Villain-Guillot P., Bastide L., Gualtieru M., Leonetti J.-P., Progress in targeting bacterial transcription, Drug Discov. Today, 2007, 12, p. 200, Copyright 2007, with permission from Elsevier.
47. Tupin A., Gualtieri M., Leonetti J.-P., Brodolin K., The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site, The EMBO J., 2010, 29, p. 2527.
48. McAlpine J. B., Hochlowski J. E., Dialkyltiacumicin compounds, Brevet WO 9635702, 1996, Abbott Laboratories.
49. Ichikawa Y., Chiu Y.-H., Shue Y.-K., Babakhani F. K., Antibiotic macrocycle compounds and methods of manufacture and use thereof, Brevet WO 2009070779 A1, 2009, Optimer Pharmaceuticals Inc.
50. Hochlowski J. E., Jackson M., Rasmussen R. R., Buko A. M., Clement J. J., Whittern D. N., McAlpine J. B., Production of brominated tiacumicin derivatives, J. Antibiot., 1997, 50, p. 201.
51. Babakhani F., Seddon J., Robert N., Shue Y.-K., Sears P., Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile, Antimicrob. Agents. Chemother., 2010, 54, p. 2674.
52. Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101, Drugs in R&D., 2010, 10, p. 37.
53. Louie T. J., Miller M. A., Mullane K. M., Weiss K., Lentnek A., Golan Y., Gorbach S., Sears P., Shue Y.-K., Fidaxomicin versus vancomycin for Clostridium difficile infection, N. Engl. J. Med., 2011, 364, p. 422; www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm257024.htm